PubRank

Amber L Beitelshees

Author PubWeight™ 48.01‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy 2012 2.49
2 The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther 2013 2.39
3 Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J 2009 2.12
4 Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet 2012 1.96
5 Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens 2010 1.90
6 Chromosome 9p21 haplotypes and prognosis in white and black patients with coronary artery disease. Circ Cardiovasc Genet 2011 1.69
7 G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension 2012 1.59
8 Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. Circ Cardiovasc Genet 2012 1.52
9 Correlates of serum matrix metalloproteinase-8 (MMP-8) concentrations in nondiabetic subjects without cardiovascular disease. Clin Chim Acta 2006 1.46
10 Loci influencing blood pressure identified using a cardiovascular gene-centric array. Hum Mol Genet 2013 1.27
11 Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 2004 1.20
12 Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program. Am J Med Genet C Semin Med Genet 2014 1.19
13 Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension 2009 1.15
14 Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenet Genomics 2007 1.15
15 Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. Hypertension 2013 1.14
16 Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genomics 2011 1.12
17 Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS One 2013 1.10
18 Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES). Am Heart J 2008 1.05
19 Discordance between availability of pharmacogenetics studies and pharmacogenetics-based prescribing information for the top 200 drugs. Ann Pharmacother 2006 1.00
20 Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Circ Cardiovasc Genet 2013 0.99
21 Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response. J Transl Med 2012 0.97
22 CXCL5 gene polymorphisms are related to systemic concentrations and leukocyte production of epithelial neutrophil-activating peptide (ENA-78). Cytokine 2006 0.92
23 Adrenergic-pathway gene variants influence beta-blocker-related outcomes after acute coronary syndrome in a race-specific manner. J Am Coll Cardiol 2012 0.92
24 Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. J Hypertens 2013 0.91
25 Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES). Circ Cardiovasc Genet 2010 0.89
26 Is diabetes mellitus-linked amino acid signature associated with β-blocker-induced impaired fasting glucose? Circ Cardiovasc Genet 2014 0.88
27 NOS3 polymorphisms are associated with arterial stiffness in children with type 1 diabetes. Diabetes Care 2007 0.87
28 Epithelial neutrophil-activating peptide (ENA-78), acute coronary syndrome prognosis, and modulatory effect of statins. PLoS One 2008 0.87
29 Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide. J Transl Med 2012 0.87
30 Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol. Am J Hypertens 2011 0.86
31 Serum monocyte chemoattractant protein-1 concentrations associate with diabetes status but not arterial stiffness in children with type 1 diabetes. Diabetes Care 2008 0.86
32 Single nucleotide polymorphism discovery and haplotype analysis of Ca2+-dependent K+ channel beta-1 subunit. Pharmacogenet Genomics 2007 0.85
33 Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide. Pharmacotherapy 2014 0.84
34 Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association. Circulation 2015 0.81
35 A PPARα promoter variant impairs ERR-dependent transactivation and decreases mortality after acute coronary ischemia in patients with diabetes. PLoS One 2010 0.80
36 PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment. Pharmacotherapy 2013 0.80
37 Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure. Pharmacotherapy 2004 0.79
38 Clopidogrel pharmacogenetics: promising steps towards patient care? Arterioscler Thromb Vasc Biol 2006 0.77
39 Association of branched and aromatic amino acids levels with metabolic syndrome and impaired fasting glucose in hypertensive patients. Metab Syndr Relat Disord 2015 0.77
40 Night blood pressure responses to atenolol and hydrochlorothiazide in black and white patients with essential hypertension. Am J Hypertens 2013 0.77
41 PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. J Hypertens 2015 0.76
42 Is ticagrelor the antiplatelet therapy panacea? Circ Cardiovasc Genet 2010 0.75
43 Re: Meckley LM, Veenstra DL. Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. Pharmacogenet Genom 2006; 16:139-147. Pharmacogenet Genomics 2006 0.75
44 Common laboratory methods in pharmacogenomics studies. Am J Health Syst Pharm 2006 0.75